If It Ain’t Broke…: FDA Committee Supports Retaining Soliris REMS
This article was originally published in RPM Report
Executive Summary
FDA’s annual REMS reviews haven’t been the most dramatic advisory committees in recent years. The latest review is the first to involve a major commercial product – Alexion’s Soliris – but also looked at a program that appears successful and non-controversial.